140 results on '"Roddie, C."'
Search Results
2. ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia
3. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
4. Targeting interference of CTLA-4 co-inhibition to tumour specific T cells to enhance activity and reduce toxicity
5. Outcome and feasibility of radiotherapy bridging in large B‐cell lymphoma patients receiving CD19 CAR T in the UK.
6. Improved outcomes of large B‐cell lymphoma patients treated with CD19 CAR T in the UK over time.
7. CAR T in patients with large B‐cell lymphoma not fit for autologous transplant.
8. Emerging options for the treatment of melanoma – focus on ipilimumab
9. Management of adults and children receiving CAR T- cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
10. LISOCABTAGENE MARALEUCEL (LISO‐CEL) VERSUS STANDARD OF CARE (SOC) AS SECOND‐LINE THERAPY IN LARGE B‐CELL LYMPHOMA (TRANSFORM STUDY): SUBGROUP ANALYSES BY PRIOR THERAPY RESPONSE.
11. Allogeneic Hematopoietic Stem Cell Transplantation and Norovirus Gastroenteritis: A Previously Unrecognized Cause of Morbidity
12. Preclinical investigation and validation of a second generation CD19 directed chimeric antigen receptor (CAR), to target diffuse large B-cell lymphoma (DLBCL) for use in a phase 1 clinical trial: 186
13. Reduced fibrinolysis and increased fibrin generation can be detected in hypercoagulable patients using the overall hemostatic potential assay
14. Exposure to multiple doses of UVB radiation reduces the numbers of epidermal Langerhans cells and lymph node dendritic cells in mice
15. Allogeneic haematopoietic stem cell transplantation and norovirus gastroenteritis: a previously unrecognised cause of morbidity: O381
16. Local effects of TL01 phototherapy in psoriasis
17. Lack of effect of oral selenite on p53 associated gene expression during TL01 therapy of psoriasis patients
18. Selenomethionine inhibits ultraviolet radiation-induced p53 transactivation
19. The laboratory diagnosis of lupus anticoagulant in patients on oral anticoagulation
20. Cutaneous Leukemia Inhibitory Factor and Its Potential Role in the Development of Skin Tumors
21. Defective Cyclic Guanosine Monophosphate-gated Calcium Channels and the Pathogenesis of Psoriasis
22. Infection of murine keratinocytes with herpes simplex virus type 1 induces the expression of interleukin-10, but not interleukin-1α or tumour necrosis factor-α
23. Leukaemia Inhibitory Factor (LIF) Expression in Skin from Amyotrophic Lateral Sclerosis Patients Compared with Skin from Normal Individuals: What is the Function of LIF in the Skin?
24. Radiotherapy Bridging in Patients With R/R High-Grade Lymphoma Receiving CD19 CAR-T in the UK
25. RADIOTHERAPY BRIDGING IN LARGE B‐CELL LYMPHOMA PATIENTS RECEIVING CD19 CAR‐T – THE UK EXPERIENCE.
26. Outcomes in patients allocated to no-ASCT based on depth of response: initial results of a phase 2 trial assessing the impact of minimal residual disease (MRD) in patients with deferred ASCT (PADIMAC)
27. Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival
28. Developing CAR‐T‐sparing Radiotherapy ‐ early dosimetric results.
29. P1460: SAFETY AND EFFICACY FINDINGS OF AUTO1, A FAST‐OFF RATE CD19 CAR, IN RELAPSED/REFRACTORY PRIMARY CNS LYMPHOMA.
30. P1459: SAFETY AND EFFICACY FINDINGS OF AUTO1, A FAST‐OFF RATE CD19 CAR, IN RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN'S LYMPHOMA (B‐NHL), AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) / SMALL LYMPHOCYTIC LYMPHOMA (SLL)
31. Mechanisms of selenium-mediated protection from photocarcinogenesis and cell death are not solely p53-dependent
32. Exposure to multiple doses of UVB radiation reduces the numbers of epidermal Langerhans cells and lymph node dendritic cells in mice.
33. Hodgkin transformation of newly diagnosed small lymphocytic lymphoma in the gastrointestinal tract.
34. Ultraviolet radiation B (UVB)-induction of Leukaemia Inhibitory Factor (LIF) in human keratinocytes.
35. Efficacy and safety of bendamustine-containing bridging therapy in R/R LBCL patients receiving CD19 CAR T-cells.
36. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysis.
37. Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy.
38. CAR-T cell manufacturing landscape-Lessons from the past decade and considerations for early clinical development.
39. Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme.
40. Outcomes after chimeric antigen receptor T-cell therapy across large B-cell lymphoma subtypes.
41. Mucormycosis after CD19 chimeric antigen receptor T-cell therapy: results of a US Food and Drug Administration adverse events reporting system analysis and a review of the literature.
42. Current Treatment Options for Renal Cell Carcinoma: Focus on Cell-Based Immunotherapy.
43. Axi-cel as a safe and effective treatment in older patients with large B-cell lymphoma.
44. High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma.
45. Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy.
46. Improved COVID-19 outcomes in CAR-T patients in the age of vaccination and preemptive pharmacotherapeutics.
47. The Emerging Role of Induced Pluripotent Stem Cells as Adoptive Cellular Immunotherapeutics.
48. Adoptive Immunotherapy via Donor Lymphocyte Infusions following Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: A Real-World, Retrospective Multicenter Study.
49. Large-scale manufacturing of base-edited chimeric antigen receptor T cells.
50. Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.